These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29293004)

  • 1. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.
    Helal CJ; Arnold E; Boyden T; Chang C; Chappie TA; Fisher E; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Pandit J; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; McGinnis D; O'Connor RE; O'Donnell CJ; Ogden A; Piotrowski M; Schmidt CJ; Seymour PA; Ueno H; Vansell N; Verhoest PR; Yang EX
    J Med Chem; 2018 Feb; 61(3):1001-1018. PubMed ID: 29293004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
    Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
    J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
    Gu G; Scott T; Yan Y; Warren N; Zhang A; Tabatabaei A; Xu H; Aertgeerts K; Gomez L; Morse A; Li YW; Breitenbucher JG; Massari E; Vivian J; Danks A
    J Pharmacol Exp Ther; 2019 Sep; 370(3):399-407. PubMed ID: 31253692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
    Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
    J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
    Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
    Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
    Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
    Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.
    Kumar J; Umar T; Kausar T; Mobashir M; Nayeem SM; Hoda N
    J Mol Model; 2017 Jan; 23(1):7. PubMed ID: 27966018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
    Hamza A; Zhan CG
    J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
    Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
    Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
    Nakashima M; Suzuki N; Shiraishi E; Iwashita H
    Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).
    Trabanco AA; Buijnsters P; Rombouts FJ
    Expert Opin Ther Pat; 2016 Aug; 26(8):933-46. PubMed ID: 27321640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Inhibition Modality for Phosphodiesterase 2A.
    Nakashima K; Matsui H
    SLAS Discov; 2020 Jun; 25(5):498-505. PubMed ID: 32343157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
    Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
    J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.
    Chen L; Nabulsi N; Naganawa M; Zasadny K; Skaddan MB; Zhang L; Najafzadeh S; Lin SF; Helal CJ; Boyden TL; Chang C; Ropchan J; Carson RE; Villalobos A; Huang Y
    J Nucl Med; 2016 Sep; 57(9):1448-53. PubMed ID: 27199356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[
    Ritawidya R; Ludwig FA; Briel D; Brust P; Scheunemann M
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31370274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
    Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Egerland U; Kranz M; Scheunemann M; Höfgen N; Steinbach J; Brust P
    Molecules; 2015 May; 20(6):9591-615. PubMed ID: 26016549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway.
    Xu Y; Pan J; Chen L; Zhang C; Sun J; Li J; Nguyen L; Nair N; Zhang H; O'Donnell JM
    Int J Neuropsychopharmacol; 2013 May; 16(4):835-47. PubMed ID: 22850435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
    Wunder F; Gnoth MJ; Geerts A; Barufe D
    Mol Pharm; 2009; 6(1):326-36. PubMed ID: 19049345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of an
    Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Kranz M; Scheunemann M; Egerland U; Höfgen N; Briel D; Steinbach J; Brust P
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.